Alert for Sage Therapeutics Shareholders
Attention, investors in Sage Therapeutics, Inc.! There’s an important deadline coming up that could significantly affect your rights. The team at Glancy Prongay & Murray LLP is reminding shareholders about the urgent deadline for filing a lead plaintiff motion in a class action lawsuit on behalf of those who purchased Sage securities during a specific time frame. This notice is essential for anyone who may have been adversely impacted by recent stock price changes.
Navigating the Legal Landscape
Right now, there's an important motion in a class action aimed at safeguarding the interests of investors who bought Sage Therapeutics (NASDAQ: SAGE) shares during certain periods. The deadline to file is fast approaching, and investors should carefully evaluate their situations. If your investments seem to have suffered, it's wise to seek legal advice. There are avenues to potentially recover losses under federal securities laws.
Recent Events Impacting Share Price
Throughout 2023 and into 2024, Sage has faced various challenges that have significantly affected its stock price. In August 2023, the FDA announced that zuranolone's approval had a constrained scope, which led to a sharp decline in the stock's value. Specifically, the stock plummeted by nearly 53.6% soon after this announcement, reflecting investor disappointment and causing substantial losses.
Additional Hurdles in Clinical Trials
Additionally, at the start of 2024, Sage reported setbacks from a Phase 2 trial concerning SAGE-718 for mild cognitive impairment linked to Parkinson's Disease. The results fell short of the expected endpoints, raising further concerns among investors. This news resulted in a significant drop in the stock's valuation, highlighting ongoing risks tied to Sage's developmental efforts.
The Impact of the Allegations
The class action claims that Sage Therapeutics misled investors by making overly optimistic statements regarding its drug candidates' effectiveness. The complaint points out that management did not disclose crucial information related to the performance and likelihood of FDA approval for key therapies. Investors should take a moment to consider these allegations and how they connect to their own investment decisions.
Steps for Shareholders
If you bought Sage securities during the identified class period, now is a critical time to take action. You don’t have to rush into any decisions unless you want to actively pursue appointment as a lead plaintiff. Keeping informed or hiring legal counsel is all you need to do right now. If you're curious about your rights in this class action, consulting with legal experts who specialize in securities litigation is highly recommended.
Obtaining More Information
If you're looking for more details on this lawsuit, you can get in touch with Glancy Prongay & Murray LLP. They are committed to safeguarding shareholders’ rights and offer resources and support for those considering their legal options. The firm encourages all affected investors to reach out for tailored advice that fits their unique situations.
Frequently Asked Questions
What is the upcoming deadline related to the Sage Therapeutics lawsuit?
The deadline to file a lead plaintiff motion in the class action is approaching, specifically by October 28, 2024.
Who can participate in the class action lawsuit?
Any investor who purchased Sage Therapeutics securities during the specified Class Period is eligible to be a part of the lawsuit.
What should I do if I lost money on Sage investments?
If you have suffered losses due to the stock price fluctuations of Sage, it’s advisable to consult legal counsel to discuss recovery options.
How can I contact Glancy Prongay & Murray LLP?
You can reach out to them directly at 310-201-9150 or Toll-Free at 888-773-9224 for further information.
What were the main issues cited in the class action lawsuit?
The lawsuit alleges that the company made misleading statements and failed to disclose vital facts about its drug candidates and their potential success.
